Lynparza (olaparib), a product of Fortune 500 pharmaceutical company Merck and Fortune 500 pharmaceutical company AstraZeneca in Europe, has shown meaningful improvements in overall survival in people with BRCA mutated (gBRCAm) and high-risk early breast cancer. HER2 negative, 2024 clinical trial data indicate.
Jaime Grajales Benjomia – Getty Images
https://fortune.com/img-assets/wp-content/uploads/2024/12/GettyImages-1400144048-e1734034203890.jpg?resize=1200,600
Source link